Skip to main content
SpringerLink
Log in

Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin’s disease

  • GENERAL INFERTILITY
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose

To examine ovarian reserve following chemotherapy in women with Hodgkin’s disease.

Methods

The study included nine patients who underwent ovarian tissue cryopreservation (OTCP) prior to chemotherapy consisting of the ABVD regimen (Adriamycin, bleomycin, vinblastine, and dacarbazine) and co-treatment with gonadotropin-releasing hormone agonist (GnRH-a) (Group A), and 13 patients treated by the ABVD protocol only without GnRH-a (Group B). The average age was 25.2 ± 2.7 years for the women in Group A and 31.8 ± 6.8 years for those in Group B.

Results

Six months following the end of chemotherapy, the menstrual cycle resumed in all Group A patients and in four Group B patients who had amenorrhea. Eight Group B patients had regular menses during and after chemotherapy. None of the patients suffered from ovarian failure. Two Group A patients conceived in the first year after completing chemotherapy.

Conclusions

Co-treatment with GnRH-a has little effect on ovarian protection in women with Hodgkin’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kogel KE, Sweetenham JW. Current therapies in Hodgkin’s disease. Eur J Nucl Med Mol Imaging. 2003;30(Suppl 1):S19–27.

    PubMed  Google Scholar 

  2. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478.

    PubMed  CAS  Google Scholar 

  3. Blumenfeld Z, Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann Med. 1997;29:199–206. doi:10.3109/07853899708999337.

    Article  PubMed  CAS  Google Scholar 

  4. Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S. Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol. 1987;19:159–62. doi:10.1007/BF00254570.

    Article  PubMed  CAS  Google Scholar 

  5. Oktay K, Sonmerz M. Ovarian tissue banking, not just ovarian cryopreservation. Hum Reprod. 2004;19:477–80. doi:10.1093/humrep/deh152.

    Article  PubMed  Google Scholar 

  6. Gosden RG, Wade JC, Fraser HM, Sandow J, Faddy MJ. Impact of congenital or experimental hypogonadotropism on radiation sensitivity of the mouse ovary. Hum Reprod. 1997;12:2483–8. doi:10.1093/humrep/12.11.2483.

    Article  PubMed  CAS  Google Scholar 

  7. Azem F, Yovel I, Wagman I, Kapostiansky R, Lessing JB, Amit A. Surrogate pregnancy in a patient who underwent radical hysterectomy and bilateral transposition of ovaries. Fertil Steril. 2003;79:1229–30. doi:10.1016/S0015-0282(03)00148-1.

    Article  PubMed  Google Scholar 

  8. Porcu E, Venturoli S. Progress with oocyte cryopreservation. Curr Opin Obstet Gynecol. 2006;18:273–9. doi:10.1097/01.gco.0000193015.96275.2d.

    Article  PubMed  Google Scholar 

  9. Meirow D, Levron J, Eldar-Geva T, Hardan I, Frideman E, Zalel Y, Schiff E, Dor J. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med. 2005;353:318–21. doi:10.1056/NEJMc055237.

    Article  PubMed  CAS  Google Scholar 

  10. Bukman A, Heineman MJ. Ovarian reserve testing and the use of prognostic models in patients with subfertility. Hum Reprod Update. 2001;7:581–90. doi:10.1093/humupd/7.6.581.

    Article  PubMed  CAS  Google Scholar 

  11. Bukulmetz O, Arici A. Assessment of ovarian reserve. Curr Opin Obstet Gynecol. 2004;16:231–7. doi:10.1097/00001703-200406000-00005.

    Article  Google Scholar 

  12. van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, Themmen AP. Serum anti mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065–71. doi:10.1093/humrep/17.12.3065.

    Article  PubMed  Google Scholar 

  13. Ficicioglu C, Kutlu T, Baglam E, Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril. 2006;85:592–6. doi:10.1016/j.fertnstert.2005.09.019.

    Article  PubMed  CAS  Google Scholar 

  14. La Marca A, Volpe A. Anti mullerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endicrinoligy. 2006;64:603–10. doi:10.1111/j.1365-2265.2006.02533.x.

    Article  Google Scholar 

  15. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006;21:2022–6. doi:10.1093/humrep/del127.

    Article  PubMed  CAS  Google Scholar 

  16. Gosden RG, Baird DT, Wade JC, Webb R. Restoration of fertility to oophoroctomized sheep by ovarian autografts stored at −196°C. Hum Reprod. 1994;9:597–603.

    PubMed  CAS  Google Scholar 

  17. Pacheco BP, Mendez Ribas JM, Milone G, Fernandez I, Kvicala R, Mila T, Di Noto A, Ortiz OC, Pavlovsky S. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol. 2001;81:391–7. doi:10.1006/gyno.2001.6181.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Racine IVF Unit, Lis Maternity Hospital, Institute of Hematology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, 6 Weizman Street, Tel-Aviv, 64239, Israel

    Foad Azem, Nivin Samara, Tanya Cohen, Dalit Ben-Yosef, Beni Almog, Joseph B. Lessing, Odeliya Goor & Ami Amit

Authors
  1. Foad Azem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nivin Samara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tanya Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dalit Ben-Yosef
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Beni Almog
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joseph B. Lessing
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Odeliya Goor
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ami Amit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Foad Azem.

Additional information

Capsule Ovarian tissue banking with combined GnRH-a and ABVD given to patients with Hodgkin’s disease minimally affects ovarian function, similar to ABVD administered alone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Azem, F., Samara, N., Cohen, T. et al. Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin’s disease. J Assist Reprod Genet 25, 535–538 (2008). https://doi.org/10.1007/s10815-008-9276-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-008-9276-4

Keywords

Search

Navigation